Get started

Regnlong

Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in ProgressIF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929... iF we do not start WW3... IF everything utterly absolute out there in the pharmaceutical industries locally and globally... IF our studies of the relation between XLV and Regeneron Pharmaceuticals is remotely correct... Then we should have struck a trough or we shall see one in the next few months Q2-Q4 = We will see a big bullish move next ! *** Risk down is (-35%) ...
NASDAQ:REGN
by samitrading
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1